Ocuphire Eyes Phase III Path For APX3330 After Mixed Trial Results

 
• By Alaric DeArment
  
Ocuphire announed topline results from its Phase II ZETA-1 trial • Source: Shutterstock

More from Clinical Trials

More from R&D